Adjuvant aVAStin Trial in high risk Melanoma - A randomised trial evaluating the VEGF inhibitor bevacizumab (Avastin), as adjuvant therapy following resection of AJCC stage IIB (T4aN0M0) IIC (T4bN0M0) and III (TxN1-sM0) cutaneous melanoma

Trial Profile

Adjuvant aVAStin Trial in high risk Melanoma - A randomised trial evaluating the VEGF inhibitor bevacizumab (Avastin), as adjuvant therapy following resection of AJCC stage IIB (T4aN0M0) IIC (T4bN0M0) and III (TxN1-sM0) cutaneous melanoma

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms AVAST-M
  • Most Recent Events

    • 13 Jul 2018 Primary endpoint (Overall survival rate) has not been met, according to results published in the Annals of Oncology.
    • 13 Jul 2018 Primary endpoint (Overall survival) has not been met, according to results published in the Annals of Oncology.
    • 13 Jul 2018 Results published in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top